NCT04707196
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 4
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with clinical evidence or history of central nervous system metastasis; Patients with leptomeningeal disease; Patients who have received prior treatment with chemotherapy (except for neoadjuvant/adjuvant chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor (e.g. Ibrance/palbociclib, abemaciclib/Verzenio, ribociclib/Kisqali); Patients with inflammatory breast cancer
https://ClinicalTrials.gov/show/NCT04707196